ArticleJournal for immunotherapy of cancer2025

Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy.

Nicole J Toney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.